Nature Reviews Drug Discovery contents September 2015 Volume 14 Number 9 pp 587-662

If you are unable to see the message below, click here to view.

Advertisement
Create A Smarter Innovation Portfolio  Identify and prioritize your best projects Create budget scenarios on-the-fly Accelerate the pace and performance of R&D investments Get the Whitepaper: foresight.decisionlens.com/pharma
TABLE OF CONTENTS
September 2015 Volume 14 Number 9		Advertisement
Impact Factor 41.908 *	In this issue Comment News and Analysis Research Highlights Reviews Also this month Article series: Cancer immunotherapy  Featured article: Big opportunities for small molecules in immuno-oncology Jerry L. Adams, James Smothers, Roopa Srinivasan & Axel Hoos	Recombinant Antibody Production Guide Choose the right rAb production service for  your Ab drug discovery  See details
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
QSP Congress will expose you to more data-driven case studies, more of the QSP experts and more solution-led discussion to ensure you don't get left behind in the QSP revolution. With 16 QSP case studies, this year's Congress will give you unprecedented access to the data and results of the leading applications of QSP from companies such as Merck, Amgen, Pfizer and GSK.  For More information: http://qsp-congress.com/
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Heartburn is a burning chest pain or discomfort that generally occurs after eating. Although a typical symptom of GERD, heartburn can occur in a number of gastroenterological conditions (such as achalasia) or indeed can be 'functional' with no organic cause. Nature Reviews Gastroenterology & Hepatology have published an infographic that provides a snapshot of heartburn, illustrating pathophysiology, insights into associated gastrointestinal conditions and management. Download it for free here.
Comment: A community-based approach to new antibiotic discovery Matthew A. Cooper p587 | doi:10.1038/nrd4706 The Community for Open Antimicrobial Drug Discovery aims to tap into the potential of the millions of compounds distributed around laboratories globally to be a source of new antibiotic leads by offering free screening for antimicrobial properties, with no strings attached. Abstract | Full Text | PDF
NEWS AND ANALYSIS		Top
Stem-cell discovery platforms yield first clinical candidates Asher Mullard p589 | doi:10.1038/nrd4708 Induced pluripotent stem cell-derived 'disease-in-a-dish' models have propelled neurological drugs from Bristol-Myers Squibb, GlaxoSmithKline and Roche into clinical trials. PDF
Alzheimer antibody drugs show questionable potential Sara Reardon p591 | doi:10.1038/nrd4709 Amyloid-targeted antibodies seem to have a small clinical benefit in patients with mild Alzheimer disease, but issues with the design and interpretation of the trials curb enthusiasm. PDF
NEWS IN BRIEF PCSK9 inhibitors are go Asher Mullard p593 | doi:10.1038/nrd4730 PDF
Crowdfunding clinical trials Asher Mullard p593 | doi:10.1038/nrd4731 PDF
Ebola vaccine yields first hopes of clinical efficacy Asher Mullard p593 | doi:10.1038/nrd4732 PDF
EMA approves first ever malaria vaccine Asher Mullard p593 | doi:10.1038/nrd4733 PDF
BIOBUSINESS BRIEFS Market watch: Forecasting market share in the US pharmaceutical market Stephane A. Regnier & David B. Ridley p594 | doi:10.1038/nrd4697 PDF
BIOBUSINESS BRIEFS Deal watch: Celgene bets big on Scripps-originated autoimmunity candidate Megan Cully p595 | doi:10.1038/nrd4716 PDF
AN AUDIENCE WITH Gloria Maldonado p596 | doi:10.1038/nrd4715 Gloria Maldonado, Executive Director of Pfizer's Center of Excellence in Precision Medicine in Chile, discusses pharma's R&D expansion into Latin America. PDF
FROM THE ANALYST'S COUCH Trends in breakthrough therapy designation Rachel R. Chizkov & Ryan P. Million p597 | doi:10.1038/nrd4717 This article analyses the first three years of the US Food and Drug Administration's breakthrough therapy designation programme, which was established to expedite development and approval of products to treat serious diseases. PDF
RESEARCH HIGHLIGHTS Top Neurodegenerative diseases: A tale of two taus in traumatic brain injury p599 | doi:10.1038/nrd4713 PDF Anticancer drugs: A one-two punch for KRAS-driven cancer p600 | doi:10.1038/nrd4710 PDF Ageing: GRBbing longevity with both insulin signalling arms p600 | doi:10.1038/nrd4711 PDF Antiviral drugs: Novel antibodies defeat dengue virus p601 | doi:10.1038/nrd4712 PDF Anticancer drugs: Repressing LXRs to starve cancer p602 | doi:10.1038/nrd4714 PDF IN BRIEF Infectious disease: New target for antimalarials | Ophthalmology: Cholesterol precursor prevents cataracts | Cancer: Targeting LSD1 in small cell lung cancer | Gene therapy: Reversing deafness PDF Drug Discovery JOBS of the week Lecturer / Senior Lecturer The University of Queensland - School of Biomedical Sciences Research Laboratory Head / Exploratory Biotherapeutics Discovery (m / f) Boehringer Ingelheim Postdoctoral Positions Available Penn State University Postdoctoral Position in Epigenetics Icahn School of Medicine at Mount Sinai Postdoctoral Associate Boston University School of Medicine, BUMC More Science jobs from Drug Discovery EVENT Modern Phenotypic Drug Discovery: Defining the Path Forward 04.02.16 Big Sky, USA More science events from
Advertisement
More Efficient HPLC/UHPLC Method Development Shimadzu's Nexara Method Scouting System enables the investigation of up to 96 unique separation conditions per sample. A transfer program allows ultra-high-speed conditions to be transferred to conventional conditions, making the system suitable for both R&D and QA/QC applications. Learn more.
REVIEWS		Top
Article series: Cancer immunotherapy Big opportunities for small molecules in immuno-oncology Jerry L. Adams, James Smothers, Roopa Srinivasan & Axel Hoos p603 | doi:10.1038/nrd4596 Small-molecule drugs have several advantages that are complementary to, and possibly synergistic with, biologic approaches for anticancer immunotherapy. This Review provides an overview of immunological pathways that can best be targeted with small molecules and discusses how these approaches fit into the armamentarium of immunotherapeutic strategies for cancer. Abstract | Full Text | PDF | Supplementary information
Strategies to increase nitric oxide signalling in cardiovascular disease Jon O. Lundberg, Mark T. Gladwin & Eddie Weitzberg p623 | doi:10.1038/nrd4623 Nitric oxide (NO) is now established as a pivotal signalling molecule in the regulation of the cardiovascular system, and it has an important role in protection against cardiovascular disease. Here, Lundberg et al. discuss the limitations of existing NO-targeting agents and assess emerging novel approaches to therapeutically modulate NO bioavailability. Abstract | Full Text | PDF
Article series: Cancer immunotherapy Oncolytic viruses: a new class of immunotherapy drugs Howard L. Kaufman, Frederick J. Kohlhapp & Andrew Zloza p642 | doi:10.1038/nrd4663 Oncolytic viruses can kill tumour cells through a dual mechanism of action; the direct lysis of cells, and the induction of an immune response. The first oncolytic virus has been approved in China, and another has been recommended for approval in the United States. This Review discusses the biology of oncolytic viruses as well as key oncolytic viruses in clinical development, and investigates the challenges associated with developing oncolytic viruses as a new therapeutic modality for cancer. Abstract | Full Text | PDF | Supplementary information
Advertisement
Droplet Digital™ PCR (ddPCR™) is leading the way Droplet Digital PCR has led to more publications and discoveries than any other digital PCR platform - over 250 studies have taken advantage of ddPCR technology. Find out how.
Erratum: ESKAPEing the labyrinth of antibacterial discovery Ruben Tommasi, Dean G. Brown, Grant K. Walkup, John I. Manchester & Alita A. Miller p662 | doi:10.1038/nrd4729 Full Text | PDF
Advertisement
Nature Plants: Call for Papers Nature Plants launched in January and covers all aspects of plants be it their evolution, genetics, development or metabolism, their interactions with the environment, or their societal significance. The journal welcomes high quality submissions and encourages you and your colleagues to consider submitting your next research paper to the journal.  Submit your next research paper to the journal.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.